PURPOSE: To assess the impact of beta-blocker therapy on quality of life (QoL) in chronic heart failure (CHF) patients receiving optimal standard medication. METHODS: Randomised controlled trials (RCT) assessing QoL with a generic or disease specific instrument were identified by searching Medline, Embase, Pascal, Cochrane Controlled Trial database, and the bibliographies of the published articles. Studies published between 1985 and 2002 were included, regardless of language of publication. Cochrane Review Manager 4.2 software was used to analyse the data and standardised mean difference (SMD) was calculated to assess the effect on QoL. RESULTS: A total of 9 trials involving 1954 patients fit into the inclusion criteria for the analysis. QoL improved more in the beta-blocker group compared to the control arm, but the SMD did not reach statistical significance (SMD, 0.07; 95%CI [-0.16, 0.02]; p = 0.13). Subgroup analysis, per type of beta-blocker and various treatment follow-up showed similar results. CONCLUSIONS: In this meta-analysis there is evidence that beta-blocker therapy, on top of standard medication, does not impair QoL. Clinicians may add beta-blockers to standard therapy without concerns of impairing QoL in patients with CHF.
PURPOSE: To assess the impact of beta-blocker therapy on quality of life (QoL) in chronic heart failure (CHF) patients receiving optimal standard medication. METHODS: Randomised controlled trials (RCT) assessing QoL with a generic or disease specific instrument were identified by searching Medline, Embase, Pascal, Cochrane Controlled Trial database, and the bibliographies of the published articles. Studies published between 1985 and 2002 were included, regardless of language of publication. Cochrane Review Manager 4.2 software was used to analyse the data and standardised mean difference (SMD) was calculated to assess the effect on QoL. RESULTS: A total of 9 trials involving 1954 patients fit into the inclusion criteria for the analysis. QoL improved more in the beta-blocker group compared to the control arm, but the SMD did not reach statistical significance (SMD, 0.07; 95%CI [-0.16, 0.02]; p = 0.13). Subgroup analysis, per type of beta-blocker and various treatment follow-up showed similar results. CONCLUSIONS: In this meta-analysis there is evidence that beta-blocker therapy, on top of standard medication, does not impair QoL. Clinicians may add beta-blockers to standard therapy without concerns of impairing QoL in patients with CHF.
Authors: Mary E Tinetti; Gail McAvay; Sandy S Chang; Yuming Ning; Anne B Newman; Annette Fitzpatrick; Terri R Fried; Tamara B Harris; Michael C Nevitt; Suzanne Satterfield; Kristine Yaffe; Peter Peduzzi Journal: J Am Geriatr Soc Date: 2011-08-24 Impact factor: 5.562
Authors: Alvin Chandra; Eldrin F Lewis; Brian L Claggett; Akshay S Desai; Milton Packer; Michael R Zile; Karl Swedberg; Jean L Rouleau; Victor C Shi; Martin P Lefkowitz; Tzvetana Katova; John J V McMurray; Scott D Solomon Journal: JAMA Cardiol Date: 2018-06-01 Impact factor: 14.676
Authors: Josep Comin-Colet; Mitja Lainscak; Kenneth Dickstein; Gerasimos S Filippatos; Patrick Johnson; Thomas F Lüscher; Claudio Mori; Ronnie Willenheimer; Piotr Ponikowski; Stefan D Anker Journal: Eur Heart J Date: 2012-01-31 Impact factor: 29.983
Authors: Ramon F Abarquez; Paul Ferdinand M Reganit; Carmen N Chungunco; Jean Alcover; Felix Eduardo R Punzalan; Eugenio B Reyes; Elleen L Cunanan Journal: ASEAN Heart J Date: 2016-03-08
Authors: Marije Bosch; Trudy van der Weijden; Richard Grol; Henk Schers; Reinier Akkermans; Louis Niessen; Michel Wensing Journal: BMC Health Serv Res Date: 2009-06-19 Impact factor: 2.655
Authors: Yvette R B M van Gestel; Sanne E Hoeks; Don D Sin; Henk Stam; Frans W Mertens; Jeroen J Bax; Ron T van Domburg; Don Poldermans Journal: Int J Chron Obstruct Pulmon Dis Date: 2009-05-07